UNSPSC 51144400: Stimulant or anorexiant piperazines

This classification denotes six-membered ring with two nitrogen atoms positioned opposite to one another, substances called piperazines, that tend to increase behavioral alertness, agitation, or excitation, or otherwise, appetite depression, thus the term STIMULANT OR ANOREXIANT PIPERAZINES.

UNSPSC 51144400 Stimulant or anorexiant piperazines is a Class code that nominally describes pharmaceutical products in a narrow chemical category, but recent state and local procurement activity shows little alignment with this specific scope. The three most recent opportunities posted under this code—a naloxone and drug deactivation systems procurement from Seminole County, Florida; a direct-to-manufacturer prescription initiative RFI from the Texas Health and Human Services Commission; and a multi-state generic pharmaceuticals and OTC products RFP from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—involve broad pharmaceutical procurement across multiple therapeutic categories and supply channels rather than piperazine-class stimulants or anorexiants. The code appears to have been applied as a catch-all for pharmaceutical purchasing rather than reflecting the narrow chemical family the code nominally describes. State and local issuing bodies using this code include county health departments, state health agencies, and multi-state cooperative purchasing alliances serving health systems and government facilities.

Activity is concentrated in three states with recent posting dates spanning early 2026 through late June 2026: Florida (Seminole County IFB60459723LAS, due July 26, 2026, seeking annual delivery of 1,900 units of naloxone and 800 safe drug deactivation systems); Texas (Texas HHS Commission RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription programs); and Minnesota (MMCAP RFP S1070000015802, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities). The MMCAP opportunity is the largest in scope, serving multiple states including Oregon through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with contract terms effective July 1, 2026. The code shows limited recent activity aligned with its nominal chemical scope and may indicate a cataloging mismatch rather than active state and local demand for piperazine-class products specifically.